Trial Profile

A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of KX-826 for Topical Use in Chinese Adult Male Patients With Androgenetic Alopecia (AGA)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jun 2026 According to Suzhou Kintor Pharmaceuticals media release, Professor Cheng Zhou is the lead principal investigators of this trial.
01 Jun 2026 According to Suzhou Kintor Pharmaceuticals media release, data from the trial were presented at the 14th World Congress for Hair Research (WCHR 2026) held in Seoul, South Korea from May 28 to 31, 2026.
18 Mar 2026 According to Kintor Pharma Media Release, the Company plans to communicate and initiate the NDA submission for KX-826 1.0% to the drug regulatory authorities in the PRC in the near term.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com